Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Add to Calendar   Friday, March 20, 2026 10:00 PM Friday, March 20, 2026 11:00 PM ET Navigating a New Frontier in Hemophilia: Evaluating the Utility of Evolving FVIIIa Mimetic Therapies to Address Unmet Needs (This activity is supported by an educational grant from Novo Nordisk, Inc.) THSNA aYaMRExkLzQZmPlsLmNx65599
Navigating a New Frontier in Hemophilia: Evaluating the Utility of Evolving FVIIIa Mimetic Therapies to Address Unmet Needs (This activity is supported by an educational grant from Novo Nordisk, Inc.)
  Friday, March 20, 2026           10:00 PM - 11:00 PM ET
 


Description

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

Hemophilia management is entering a new era with innovative factor and nonfactor therapies. This activity explores new and emerging next-generation agents designed to overcome traditional challenges, such as inhibitor development, frequent dosing, and treatment burden. By using interactive, case-based scenarios, learners will develop the expertise needed to individualize patient selection and seamlessly integrate approved and emerging next-generation mimetics into routine practice, fostering a patient-centered approach.

1.0 AMA PRA Category 1 Credit�

Register Here: https://hemophiliathsna26.eventbrite.com/


This Content is Locked.
Log into a registered attendee account that includes registration for this event/session to access this content.